(Q56337625)

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

George C. Griffith lecture. The role of renin in normal and pathological cardiovascular homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

The response of blood pressure to infusion of angiotensin II: relation to plasma concentrations of renin and angiotensin II.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Reciprocal influence of salt intake on adrenal glomerulosa and renal vascular responses to angiotensin II in normal man.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

A specific orally active inhibitor of angiotensin-converting enzyme in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Angiotensin II blockade in normal man: interaction of renin and sodium in maintaining blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Angiotensin I converting enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive Agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Captopril (SQ 14,225) (d-3-mercapto-2-methylpropanoyl-l-proline): A novel orally active inhibitor of angiotensin-converting enzyme and antihypertensive agent

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Oral Angiotensin-Converting Enzyme Inhibitor in Long-Term Treatment of Hypertensive Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Antihypertensive Effect of the Oral Angiotensin Converting-Enzyme Inhibitor SQ 14225 in Man

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Captopril, angiotensin II, and sodium in blood-pressure regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Angiotensin II, aldosterone and arterial pressure: a quantitative approach. Arthur C. Corcoran Memorial Lecture

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Inhibitors of the renin-angiotensin system in experimental hypertension, with a note on the measurement of angiotensin I, II and III during infusion of converting-enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Hyponatraemic hypertensive syndrome with renal-artery occlusion corrected by captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Long-term effects of captopril (SQ14 225) on blood-pressure and hormone levels in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natruiresis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Converting enzyme inhibition with an orally active compound in hypertensive man

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Arterial Wall or Plasma Renin in Hypertension?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Converting enzyme inhibition in essential hypertension: the hypotensive response does not reflect only reduced angiotensin II formation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Mechanism of blood pressure reduction by teprotide (SQ 20881) in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Converting enzyme inhibitor and saralasin infusion in rats. Evidence for an additional vasodepressor property of converting enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Mechanism of renal hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Blood pressure and plasma angiotensin II concentration after renal artery constriction and angiotensin infusion in the dog. (5-Isoleucine)angiotensin II and its breakdown fragments in dog blood

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

The relation of arterial pressure and plasma angiotensin II concentration. A change produced by prolonged infusion of angiotensin II in the conscious dog

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

A slowly developing pressor response to small concentrations of angiotensin. Its bearing on the pathogenesis of chronic renal hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Arterial hypertension elicited by subpressor amounts of angiotensin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Correction of renal hypertension in the rat by prolonged infusion of angiotensin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Antihypertensive Effect of Prolonged Blockade of Angiotensin Formation in Benign and Malignant, one- and two-Kidney Goldblatt Hypertensive Rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Chronic antihypertensive effects of captopril (SQ 14,225), an orally active angiotensin I-converting enzyme inhibitor, in conscious 2-kidney renal hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Plasma Renin Concentration and the Control of Blood Pressure in Patients on Maintenance Haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Abnormal relation between exchangeable sodium and the renin-angiotensin system in malignant hypertension and in hypertension with chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Hypertension in chronic renal failure. An abnormal relation between sodium and the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Hypertension and chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Effect of beta-adrenergic blockade on plasma-renin activity and intractable hypertension in patients receiving regular dialysis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Hemodialysis-Resistant Hypertension: Control with an Orally Active Inhibitor of Angiotensin-Converting Enzyme*

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Innappropriate renin secretion unmasked by captopril (SQ 14 225) in hypertension of chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Reversal of Vascular and Renal Crises of Scleroderma by Oral Angiotensin-Converting-Enzyme Blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Renin relationships in congestive cardiac failure, treated and untreated

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Improvement of chronic congestive heart-failure by oral captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Angiotensin converting enzyme inhibition in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Reversible renal failure during treatment with captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Temporary ageusia related to captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Nephrotic syndrome in patient on captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Captopril in Hypertension with Renal Artery Stenosis and in Intractable Hypertension; Acute and Chronic Changes in Circulating Concentrations of Renin, Angiotensins I and II and Aldosterone, and in Body Composition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Angiotensin II and Renal Hypertension in Dog, Rat and Man: Effect of Converting Enzyme Inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021

Increased Glomerular Filtration Rate after Converting-Enzyme Inhibition in Essential Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2992186-X

7 January 2021